Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04413253 · ClinicalTrials.gov registry record · Phase 4
Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease
A Phase 4 study, sponsored by Eye Surgeons of Indiana.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT04413253 is a Phase 4 study that was terminated before completion, run by Eye Surgeons of Indiana. The registered enrollment target is 5 participants.
The verdict
NCT04413253, a Phase 4 study, was terminated before completion, sponsored by Eye Surgeons of Indiana.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.
Interventions
- DRUG Lifitegrast 5% Ophthalmic Solution
- DRUG Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04413253
The ClinicalTrials.gov registry entry for NCT04413253 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eye Surgeons of Indiana, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lifitegrast 5% Ophthalmic Solution is the first listed.
NCT04413253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04413253 about?
NCT04413253 is a clinical study titled "Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease". To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.
What is the current status of trial NCT04413253?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2020-08-01. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT04413253?
The interventions under investigation include: Lifitegrast 5% Ophthalmic Solution (DRUG), Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04413253?
This trial is sponsored by Eye Surgeons of Indiana, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.